Literature DB >> 17850375

Molecular markers and mortality in prostate cancer.

John Concato1, Dhanpat Jain, William W Li, Harvey A Risch, Edward M Uchio, Carolyn K Wells.   

Abstract

OBJECTIVE: To evaluate prognosis in prostate cancer by assessing the independent effect of selected molecular factors (e.g. markers of cell-cycle regulation), in addition to the effect of traditional clinical factors (e.g. anatomical stage, histological grade), in predicting long-term mortality among men newly diagnosed with prostate cancer. PATIENTS AND METHODS: In a community-based population of 64 545 USA veterans aged >/= 50 years and receiving ambulatory care during 1989-90 at nine Veterans Affairs (VA) medical centres in New England, 1274 had incident prostate cancer during 1991-95. We obtained the medical records and diagnostic tissue for these men, and then extracted demographic data and clinical information, and conducted immunohistochemical assays of molecular markers in biopsy tissue, as potential prognostic factors. In this interim analysis, data on 250 patients were analysed; the main outcome was overall mortality to 31 December 2003, providing 8-13 years of follow-up.
RESULTS: In 228 (91%) patients with available medical record and laboratory data, the median age was 72 years and the median prostate-specific antigen level was 10.4 ng/mL. In adjusted (multivariate) analyses that included traditional prognostic factors, bcl-2 staining (hazard ratio 2.14, 95% confidence interval 1.27-3.58, P = 0.004) and high microvessel density (1.76, 1.19-2.60; P = 0.005) had an independent effect on the outcome.
CONCLUSIONS: Bcl-2 and microvessel density are independent predictors of subsequent death among men with prostate cancer and might have a clinical role in assisting in deciding on treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17850375     DOI: 10.1111/j.1464-410X.2007.07136.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  11 in total

Review 1.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

Review 2.  Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging.

Authors:  Kirsten Bouchelouche; Baris Turkbey; Peter Choyke; Jacek Capala
Journal:  Curr Urol Rep       Date:  2010-05       Impact factor: 3.092

Review 3.  MRI for men undergoing active surveillance or with rising PSA and negative biopsies.

Authors:  Orit Raz; Masoom Haider; John Trachtenberg; Dan Leibovici; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2010-10       Impact factor: 14.432

4.  Ultrasound multiple scattering with microbubbles can differentiate between tumor and healthy tissue in vivo.

Authors:  Kaustav Mohanty; Virginie Papadopoulou; Isabel G Newsome; Sarah Shelton; Paul A Dayton; Marie Muller
Journal:  Phys Med Biol       Date:  2019-05-31       Impact factor: 3.609

Review 5.  New horizons in prostate cancer imaging.

Authors:  Gregory Ravizzini; Baris Turkbey; Karen Kurdziel; Peter L Choyke
Journal:  Eur J Radiol       Date:  2008-11-07       Impact factor: 3.528

Review 6.  Imaging techniques for prostate cancer: implications for focal therapy.

Authors:  Baris Turkbey; Peter A Pinto; Peter L Choyke
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

7.  Prognostic value of microvessel density in prostate cancer: a tissue microarray study.

Authors:  Andreas Erbersdobler; Hendrik Isbarn; Kira Dix; Isabel Steiner; Thorsten Schlomm; Martina Mirlacher; Guido Sauter; Alexander Haese
Journal:  World J Urol       Date:  2009-08-28       Impact factor: 4.226

8.  Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study.

Authors:  Lorelei A Mucci; Anna Powolny; Edward Giovannucci; Zhiming Liao; Stacey A Kenfield; Rulong Shen; Meir J Stampfer; Steven K Clinton
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

Review 9.  [Immunohistochemical algorithms in prostate diagnostics: what's new?].

Authors:  G Kristiansen
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

10.  The prognostic significance of vasohibin-1 expression in patients with prostate cancer.

Authors:  T Kosaka; Y Miyazaki; A Miyajima; S Mikami; Y Hayashi; N Tanaka; H Nagata; E Kikuchi; K Nakagawa; Y Okada; Y Sato; M Oya
Journal:  Br J Cancer       Date:  2013-04-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.